Age: 43

Without RxMapper: Katie is a 43 year-old mother of three young children and breast cancer patient, who was preparing to begin a 5-year Tamoxifen regimen.

With RxMapper: Analysis of her DNA revealed that Katie has three distinct genes that indicate poor long term outcomes with the use of Tamoxifen. An RxMapper Network Pharmacist shared this evidence with Katie’s oncologist and recommended an alternative treatment of Anastrozole in combination with Lupron.

Improved Outcomes: This switch, based on her DNA, greatly improves the likelihood of a successful outcome in which her cancer remains in full remission.

Age: 52

Without RxMapper: Having suffered treatment failure with methotrexate, he would be prescribed HUMIRA at a cost of $6,300 a month, $75,600 per year, and would have to endure painful injections into his stomach twice a month.

With RxMapper: Matthew gets a one-on-one consult. Based on his DNA, an RxMapper Network Pharmacist recommends leflunomide, an oral medication that is easy to take and much more effective at treating Matthew’s arthritis; and it costs just $22 a month / $264 a year.

Improved Outcome: With RxMapper, Matthew feels better because he is able to effectively treat his arthritis and saves $75,300 each year.

Age: 34

Without RxMapper: Diagnosed with ulcerative colitis, Julie was prescribed HUMIRA at a cost of $6,300 a month, $75,600 per year, and would have to endure painful injections into her stomach twice a month. Unfortunately, she lacks the protein structure needed to metabolize the drug and her colitis worsened.

With RxMapper: Julie gets personalized medication advice. Based on her DNA, an RxMapper Network Pharmacist recommends azathioprine, an oral medication that is easy to take and much more effective at treating Julie’s ulcerative colitis; and it costs just $13.20 a month / $158.40 per year.

Improved Outcomes: With RxMapper, Julie feels better because she is able to effectively treat her colitis and saves $75,400 each year.

Age: 17

Juvenile rheumatoid arthritis: Patient was seeking an alternative treatment to infliximab infusions, which compromises her immune systems leading to chronic cold and flu. Patient has a preference for oral medications.

Recommendation: RxMapper recommended sulfasalazine tablets that are likely to have an increased response, an increased likelihood of remission, and an annual reduction in drug spend of $38,580.

Uncontrolled Anxiety: Patient’s DNA sequencing results indicated a decreased response to fluoxetine, the medication she was taking.

Recommendation: RxMapper recommended citalopram, which is likely to have an increased response and decreased risk of side effects, and an annual reduction in drug spend of $12.

Age: 49

The patient suffers from uncontrolled type II diabetes mellitus and was seeking review of his current drug regimen to determine if there are alternative medication options that are preferable to his current regimen.

Recommendations: Based on the patient's DNA sequencing results, RxMapper determined that the patient’s Ozempic dose was too low to be effective. RxMapper recommended slowly increasing the patient’s Ozempic dose to address his blood sugar control needs.

Patient Follow-up: Patient confirmed provider agreed with our recommendation and dose change was implemented. Patient reports tolerating dose change well and A1c improved with new dose, and there was no cost difference.

Age: 51

Patient stopped all medications because she found them to be ineffective and has missed 40 days of work in the last two months while on FMLA leave trying to get these conditions under control. She is seeking RxMapper’s help to identify the best regimen for her health concerns.

Recommendations: RxMapper confirmed that Vraylar and generic Vyvanse are likely to be safe and effective based on the patient’s DNA and recommended starting at a lower dose and gradually increasing because of time off these medications. No change in drug costs.

Patient Follow-up: RxMapper recommended taking Wellbutrin (bupropion), due to its favorable side effect profile and additional benefit to assist in smoking cessation at a monthly cost of $14. 

Age: 61

The patient is taking multiple agents for blood pressure management and is  requesting a review of full medication regimen to assess potential for simplification to regimen. 

Recommendations: RxMapper optimized a patient's regimen by switching lisinopril to telmisartan, replacing hydrochlorothiazide and triamterene with amlodipine, and identifying a combo pill with telmisartan and amlodipine. This increased efficacy, decreased side effects, and benefited blood sugar management while reducing the number of pills taken.

Patient Follow-up: Patient requested an RxMapper review for gabapentin to treat neuropathy. RxMapper confirmed gabapentin as an optimal choice based on the patient's DNA, potentially increasing response and allowing lower dosing. The patient comfortably initiated the medication with no cost difference.

Age: 43

The patient was struggling to find effective medications to treat her severe anxiety and uncontrolled psoriatic arthritis.

Recommendations: RxMapper recommended discontinuing three ineffective medications and starting two medications that are likely to be safe and effective based on her DNA. 

Severe Anxiety: Discontinue Bupropion and switch Sertraline to Fluoxetine. The switch results in an enormous improvement in quality of life and an annual reduction in drug spend of $168.  

Uncontrolled Psoriatic Arthritis: Switch from Cosentyx (secukinumab) to Orencia (abatacept). Orencia is likely to be an effective agent for patient’s psoriatic arthritis and the switch results in an annual reduction in drug spend of $31,656.